Navigation Links
Regeneron Announces Settlement of Patent Litigation with Genentech for U.S. Ophthalmic Sales of EYLEA™ (aflibercept) Injection
Date:1/3/2012

TARRYTOWN, N.Y, Jan. 3, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the Company has entered into a non-exclusive license and partial settlement agreement (Agreement) with Genentech, Inc., a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) relating to U.S. ophthalmic sales of EYLEA™ (aflibercept) Injection.

Regeneron received a non-exclusive license to certain patents relating to VEGF receptor proteins, known as the Davis-Smyth patents, and other technology patents.  The Davis-Smyth patents are the subject of patent litigation between Regeneron and Genentech now pending in the United States District Court, Southern District of New York.  Patent litigation is continuing with respect to matters not covered by the Agreement.

Under the terms of the Agreement, Regeneron will make payments to Genentech based on U.S. sales of EYLEA through May 7, 2016.  Regeneron will pay $60 million upon cumulative U.S. sales of EYLEA reaching $400 million.  Regeneron will also pay royalties of 4.75% on cumulative U.S sales of EYLEA between $400 million and $3 billion and 5.5% on any cumulative U.S sales of EYLEA over $3 billion.

About Regeneron PharmaceuticalsRegeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets two products, ARCALYST® (rilonacept) Injection For Subcutaneous Use and EYLEA™ (aflibercept) Injection.  Regeneron also has completed several Phase 3 studies and is conducting an additional Phase 3 clinical trial for the product candidate ZALTRAP® (aflibercept) Concentrate for Intravenous Infusion.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions, and cancer.  Additional information about Regeneron and recent news releases are available on the Regeneron web site at www.regeneron.com.

Regeneron Forward-Looking StatementThis news release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron, and actual events or results may differ materially from these forward-looking statements.  These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of EYLEA and Regeneron's product candidates and research and clinical programs now underway or planned, the likelihood and timing of possible regulatory approval and commercial launch of Regeneron's late-stage product candidates, determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize EYLEA and other products and drug candidates, competing drugs that may be superior to EYLEA and Regeneron's products and drug candidates, uncertainty of market acceptance of EYLEA and Regeneron's products and drug candidates, the possibility of EYLEA sales meeting or exceeding any of the cumulative U.S. sales targets triggering payments to Genentech described in this news release, unanticipated expenses, the availability and cost of capital, the costs of developing, producing, and selling products, the potential for any license or collaboration agreement, including Regeneron's agreements with Sanofi and Bayer HealthCare, to be canceled or terminated without any product success, and risks associated with third party intellectual property and pending or future litigation relating thereto.  A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2010 and Form 10-Q for the quarter ended September 30, 2011.  Regeneron does not undertake any obligation to update publicly any forward-looking statement, whether as a result of new information, future events, or otherwise, unless required by law.Contact Information:  

 Michael Aberman, M.D.Peter DworkinInvestor RelationsCorporate Communications914.847.7799914.847.7640michael.aberman@regeneron.competer.dworkin@regeneron.com


'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Regeneron to Host Conference Call on January 3 at 8:30 a.m. Eastern Time to Discuss Ongoing Patent Litigation
2. Regeneron Announces Presentation Time Change at the 2011 Deutsche Bank BioFEST
3. Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review
4. Rockefeller University President Marc Tessier-Lavigne Elected to Regeneron Board of Directors
5. Regeneron Announces FDA Approval of EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration
6. Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia
7. Regeneron Pharmaceuticals Announces Pricing of Offering of Convertible Senior Notes due October 1, 2016
8. Regeneron Ranked by Science Magazine as the #2 Employer in the Global Biopharmaceutical Industry
9. Regeneron Announces Clinical Presentations at ASRS 2011 Annual Meeting
10. Regeneron Reports Second Quarter 2011 Financial and Operating Results
11. Sanofi and Regeneron Report Positive Phase 2b Trial Results with Sarilumab in Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... PALMA, Spain , January 23, ... a clinical-stage biopharmaceutical company focused on treatments for ... has been enrolled in the Phase IIb "CaLIPSO ... the treatment of cardiovascular calcification (CVC) in end-stage-renal-disease ... ESRD patients, in the last stage of chronic ...
(Date:1/21/2017)... , Jan 20, 2017 Research ... Clinical Laboratory Testing Market By Type of Test (Tumor, Clinical ... & By Type of Diseases (Tuberculosis, Influenza, Cancer, HIV/AIDS etc.), ... ... attractive destination for healthcare services, market segments, especially clinical lab ...
(Date:1/21/2017)... -- Research and Markets has announced the addition of ... Route Of Administration, End User - Forecast to 2025" report ... ... a CAGR of around 7.8% over the next decade to reach ... analyzes the global markets for Advanced Drug Delivery across all the ...
Breaking Medicine Technology:
(Date:1/23/2017)... Switzerland (PRWEB) , ... January 23, 2017 , ... ... lab and production applications. However, choosing the right method is paramount to success. ... occur more often in situations where multiple persons use the same equipment. Rare ...
(Date:1/23/2017)... ... 2017 , ... Old School Labs™, makers of the wildly popular all-natural sports ... Ansley to its growing team of brand ambassadors. The Olympia top finisher and former ... than a year was able to turn professional, participating in the 2013 NPC USA ...
(Date:1/23/2017)... ... ... at the Mill”: a story of love and redemption, hope and uncertainty as a ... , “The Inn at the Mill” is the creation of published author, Lois Kulp, ... now living in Berks County on Crow Hill. The inn, the mill and ...
(Date:1/23/2017)... ... ... “Life Under Blankets”: an entrancing story about one woman's travels through the wilderness ... of published author, Kimberly Mitchell, who earned her bachelor’s degree in English education at ... master’s degree in education in the field of curriculum and instruction. Kimberly’s passion for ...
(Date:1/22/2017)... FRANCE (PRWEB) , ... January 22, 2017 , ... Phytocéane ... Ocean, isolated from the rest of the world with ZANZIBAR MILKY CREAM. Inspired by ... used key ingredients like Virgin Coconut Oil and moisturizing vegetal coral to create this ...
Breaking Medicine News(10 mins):